
201 - 500 employees
Founded 2008
🧬 Biotechnology
🏥 Healthcare
🔥 Funding within the last year
💰 $100M Post-IPO Equity on 2026-07
Biotechnology • Healthcare
REGENXBIO is a leading clinical-stage biotechnology company focused on developing and commercializing gene therapies using its proprietary NAV® adeno-associated virus (AAV) technology platform. The company is advancing multiple late-stage clinical programs and candidates targeting retinal and rare diseases (examples in its pipeline include ABBV‑RGX‑314 for retinal disease, RGX‑202 for Duchenne, and RGX‑121 for MPS II/ Hunter syndrome). REGENXBIO emphasizes one-time curative treatments, in-house commercial-ready manufacturing, and collaboration with partners and licensees to expand its AAV vector library and therapeutic reach.
🔥 1 hour ago
Where this job comes from
Posted on REGENXBIO's careers page, not through a job board
First seen by Remote Rocketship 1 hour ago
Still open on REGENXBIO's site. Checked 1 minute ago.

201 - 500 employees
Founded 2008
🧬 Biotechnology
🏥 Healthcare
🔥 Funding within the last year
💰 $100M Post-IPO Equity on 2026-07
Biotechnology • Healthcare
REGENXBIO is a leading clinical-stage biotechnology company focused on developing and commercializing gene therapies using its proprietary NAV® adeno-associated virus (AAV) technology platform. The company is advancing multiple late-stage clinical programs and candidates targeting retinal and rare diseases (examples in its pipeline include ABBV‑RGX‑314 for retinal disease, RGX‑202 for Duchenne, and RGX‑121 for MPS II/ Hunter syndrome). REGENXBIO emphasizes one-time curative treatments, in-house commercial-ready manufacturing, and collaboration with partners and licensees to expand its AAV vector library and therapeutic reach.
• Lead the overall strategy and commercialization of REGENXBIO’s rare disease portfolio • Own rare disease franchise business performance and P&L, including revenue, profitability, forecasting, budget, resource allocation, and commercial objectives • Lead development and execution of the rare disease franchise strategy and commercialization roadmap for RGX-202 and future programs and products • Establish business objectives, performance metrics, and operating plans • Own the annual operating plan, revenue forecast, expense budget, and resource allocation • Assess market, competitive, customer, and business performance and adjust strategy and investments • Partner with Finance and executive leadership on financial rigor and accountability • Develop and oversee the integrated U.S. launch strategy and market entry plan for RGX-202 • Establish launch objectives, readiness milestones, performance measures, and operating plans • Address launch barriers involving market development, patient identification and referral, treatment-center readiness, access and reimbursement, and patient onboarding • Manage franchise revenue, demand generation, operating expenses, planning, forecasting, performance management, investment decisions, risks, opportunities, and sustainable growth • Align with executive and senior leadership on global commercialization strategy and plans • Translate enterprise strategy into franchise priorities, operating plans, and measurable outcomes • Drive cross-functional alignment and accountability for commercial and franchise initiatives • Contribute to commercialization, portfolio prioritization, business development, and resource allocation decisions • Represent the rare disease community in company strategy and decision-making • Partner with R&D on the rare neuromuscular and muscle franchise and lead cross-functional leadership and strategy plans • Align commercial, clinical, medical, regulatory, market access, and operational priorities • Inform pipeline strategy and development priorities using market, customer, patient, and competitive insights • Provide commercial and market development input into development plans and lifecycle strategies • Elevate external leadership in rare diseases through industry thought leadership, symposia, and key associations • Report to the Chief Commercial Officer • Lead the Rare Disease Franchise and Marketing organization
• Advanced degree in relevant life sciences or finance (Ph.D., MBA, MS) is required • 15+ years progressive commercial leadership experience in biotechnology or pharmaceuticals • Experience leading substantial commercial teams and/or businesses • Demonstrated experience successfully leading a product launch and/or significant leadership accountability for launch strategy, readiness, and execution • Ability to translate commercial and franchise strategy into clear business priorities and performance expectations • Strong business and financial acumen, including responsibility for revenue, operating budgets, forecasting, resource allocation, and investment decisions • Experience operating effectively in highly cross-functional environments and influencing senior leaders across Commercial, Medical, R&D, Market Access, Finance, and other functions • Ability to build organizations and capabilities, develop high-performing teams, and lead through ambiguity and change • Ability to travel as required • Preferred: significant rare disease commercial leadership experience • Preferred: experience commercializing therapies with complex patient journeys, concentrated treatment-center models, and institutional access and reimbursement requirements • Preferred: experience with gene therapy, one-time therapies, biologics, and/or complex specialty treatment models • Preferred: experience contributing to lifecycle, pipeline, portfolio, or business-development decisions from a commercial perspective
• Annual bonus program • Education assistance • Retirement plan with employer match • Stock options at all levels • Summer hours • Professional development opportunities • Access to development resources • Challenging projects • Market-competitive salary
Apply NowImprove your chances of getting an interview by checking your resume score before you apply.
🔥 1 hour ago
VP managing client relationships, trust responsibilities, and business growth for Ultimus Fund Solutions. Leading client strategies, service partnerships, fund conversions, and cross-selling initiatives.
🔥 1 hour ago
Enterprise sales executive selling nCino’s Bank Operating System to US financial institutions over $25 billion in assets. Managing complex B2B sales cycles and expanding enterprise client adoption.
🇺🇸 United States – Remote
💵 $100k - $185k / year
💰 $925.6M Post-IPO Equity on 2022-01
⏰ Full Time
🔴 Lead
👔 Vice President
🔥 1 hour ago
Vice President leading analytics and decision science for MissionOne Media, a full-funnel media planning and buying agency. Developing measurement strategies, advising clients, and scaling analytics teams.
🔥 1 hour ago
VP of Social leading national social strategy, content, partnerships, and audience growth for pro-democracy news network COURIER. Managing the social team and performance optimization across major platforms.
🔥 1 hour ago
VP leading Known’s corporate affairs, communications, and public policy strategy. Shaping trust infrastructure adoption for AI agents and autonomous systems.